Immune-checkpoint inhibitors (ICIs) are more promising to treat Non-small cell lung cancer (NSCLC) compared to standard drugs. But, certain patients still develop the disease after using ICI. The study published in iClinical Cancer Research/i, suggests an additional treatment option for patients who progress after ICI.
Several ICI agents have been approved in recent years to treat NSCLC, including nivolumab, atezolizumab and pembrolizumab. ICIs function by stimulating the immune system to target cancer cells for destruction....
Immune-checkpoint inhibitors (ICIs) are more promising to treat Non-small cell lung cancer (NSCLC) compared to standard drugs. But, certain patients still develop the disease after using ICI. The study published in iClinical Cancer Research/i, suggests an additional treatment option for patients who progress after ICI.
Several ICI agents have been approved in recent years to treat NSCLC, including nivolumab, atezolizumab and pembrolizumab. ICIs function by stimulating the immune system to target cancer cells for destruction....